Biological effects of hormone replacement therapy in relation to serum estradiol levels

Hormone Research

Volumn 56, Issue 1-2, 2001, Pages 38-44

  Yasui, Toshiyuki ^a,c   Uemura, Hirokazu ^a   Tezuka, Michiko ^a   Yamada, Masayo ^a   Irahara, Minoru ^a   Miura, Masakazu ^b   Aono, Toshihiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bone; Estradiol; Gonadotropin; Hormone replacement therapy; Lipid

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BLEEDING; BONE DENSITY; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; FEMALE; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIPID METABOLISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME; VAGINA ATROPHY; VASOMOTOR REFLEX;

ADULT; BONE DENSITY; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LIPIDS; LUMBAR VERTEBRAE; LUTEINIZING HORMONE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OVARIECTOMY; POSTMENOPAUSE; PROGESTERONE CONGENERS; UTERINE HEMORRHAGE;

EID: 0035707994     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048088     Document Type: Article

References (23)

1. Hormone treatment of endometriosis: The estrogen threshold hypothesis
2. Biologic effects of transdermal estradiol
3. 17β-estradiol for postmenopausal estrogen replacement therapy
4. Combination of automatic HPLC-RIA method for determination of estrone and estradiol in serum
5. Hormone replacement therapy and the risk of first hip fracture: A prospective population-based cohort study
6. Postmenopausal estrogen therapy and cardiovascular disease: Ten years follow-up from the Nurses' Health Study
7. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
8. Breast Cancer and HRT: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
9. The minimum effective dose of estrogen for the prevention of post-menopausal bone loss
10. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period
11. Effect of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in post-menopausal women
12. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
13. Compliance with hormone therapy
14. Continuous combined estrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis
15. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
16. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins
17. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study
18. Effects of oral and transdermal hormone replacement therapy in relation to serum estrogen levels
19. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
20. Metabolic parameters and steroid levels in postmenopausal women receiving lower doses of natural estrogen replacement
21. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy
22. Biological effects of equilin sulfate in post-menopausal women
23. Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women